Clinical trials: Controlled Diabetes
Diabetes Mellitus, Non-Insulin-Dependent
MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
The phase III clinical trial examines the efficacy, safety, and tolerability of the addition of MK0431/ONO-5435 to Japanese patients with type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT00837577
- Testing
- Sitagliptin, Voglibose
- Volunteers
- 133 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Fasiglifam 25 mg BID vs 50 mg QD
To evaluate the efficacy of fasiglifam 25 mg twice daily (BID) and fasiglifam 50 mg once daily (QD) on glycemic control in adults with type 2 diabetes who are inadequately controlled on diet and exercise alone.
- Trial name
- NCT01982253
- Testing
- Fasiglifam
- Where
- 88 sites in United States, Bulgaria and 5 more
- Volunteers
- 10 people
- Sponsor
- Takeda
Diabetic Kidney Disease
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced Diabetic Kidney Disease
The primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
- Trial name
- MOSAIC (NCT04026165)
- Testing
- SEL
- Where
- 111 sites in United States, Australia and 3 more
- Volunteers
- 384 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type II, Obesity
A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus
An exploratory study to evaluate the effect of MEDI0382 on energy balance in overweight and obese participants with type 2 diabetes mellitus
- Trial name
- NCT03596177
- Testing
- MEDI0382
- Where
- United Kingdom
- Volunteers
- 28 people
- Sponsor
- MedImmune LLC
Diabetic Nephropathies
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic Kidney Disease
This study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study.
- Trial name
- NCT04750577
- Testing
- BI 685509
- Where
- 78 sites in United States, Argentina and 14 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Social Media-Delivered Patient Education in Enhancing Type 2 Diabetics Self-Management and Attitudes During the COVID-19 Pandemic
The current study was to develop a software "Line@" based health education program, providing video-based health information and communication between diabetes patients and health-care professionals.
- Trial name
- NCT04876274
- Testing
- TMU-LOVE
- Where
- Taiwan
- Volunteers
- 181 people, healthy volunteers welcome
- Sponsor
- Taipei Medical University
Apathy, Diabetes
The Role of Apathy in Glycemic Control
In spite of several new medications and insulins for the control of blood sugars in patients with diabetes, a large number of patients do not have good control.
- Trial name
- NCT00844090
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- US Department of Veterans Affairs
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN1250 With Insulin Glargine in Type 2 Diabetes
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes.
- Trial name
- BEGIN™ (NCT01006291)
- Testing
- insulin degludec, insulin glargine
- Where
- 72 sites in Argentina, Finland and 12 more
- Volunteers
- 687 people
- Sponsor
- Novo Nordisk A/S
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients
The purpose of this study was to assess the effects of LIK066 on a variety of metabolic and inflammation biomarkers in patients with non-alcoholic steatohepatitis (NASH)
- Trial name
- NCT03205150
- Testing
- LIK066
- Where
- 15 sites in United States, Argentina and 6 more
- Volunteers
- 107 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Diabetes Distress
Behavioral Approaches to Reducing Diabetes Distress and Improving Glycemic Control
This study is comparing three programs to reduce Diabetes Distress (the worries and concerns that people with diabetes may experience as they struggle to keep blood glucose levels in range) in adults with type 1 diabetes.
- Trial name
- EMBARK (NCT04016558)
- Testing
- StreamLine, TunedIn, FixIt
- Where
- United States
- Volunteers
- 296 people
- Sponsor
- University of California, San Francisco
Atherosclerosis, Cardiovascular Diseases
Intensive Glycemic Control and Skeletal Health Study
The purpose of the ACCORD-BONE Study is to investigate the effects of intensive glycemic control for type 2 diabetes (in ACCORD participants) on factors related to bone health, including, fractures, falls, and bone mineral…
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension
- Trial name
- ACCORD-BONE (NCT00324350)
- Testing
- hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents
- Where
- 5 sites in United States, Canada
- Volunteers
- 7,287 people
- Sponsor
- University of California, San Francisco
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes
Safety and Efficacy of Combination Saxagliptin & Dapagliflozin Added to Metformin to Treat Subjects With Type 2 Diabetes
The purpose of this study is to learn if a combination of BMS-477118 (Saxagliptin) and BMS -512148 (Dapagliflozin) added to Metformin can improve (decrease) Glycosylated Hemoglobin (Hemoglobin A1c) in patients with type 2…
- Trial name
- NCT01606007
- Testing
- Saxagliptin, Metformin XR, Dapagliflozin
- Where
- 139 sites in United States, Canada and 6 more
- Volunteers
- 1,282 people
- Sponsor
- AstraZeneca
Diabetes Mellitus
The Guardcontrol Trial: Study to Assess if Type 1 Diabetics Can Improve Using the Real-time Values of Guardian RT
The objective of the study is to determine whether patients with poor glycemic control can improve metabolic control using the real-time values of the Guardian® RT compared to conventional self-monitoring blood glucose…
- Trial name
- NCT00111228
- Testing
- Guardian RT, SMBG only
- Where
- 8 sites in France, Germany and 5 more
- Volunteers
- 162 people
- Sponsor
- Medtronic MiniMed, Inc.
Organizational Support for Evidence-based Public Health
Disseminating Public Health Evidence to Support Prevention and Control of Diabetes Among Local Health Departments
The purpose of this study is to identify and evaluate dissemination strategies to support the uptake of evidence-based programs and policies (EBPPs) for diabetes prevention and control among local-level public health…
- Trial name
- NCT03211832
- Testing
- Dissemination of public health knowledge
- Where
- United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Pre Diabetes, Polycystic Ovary Syndrome
Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOS
There is a growing need to develop pharmacologic interventions to improve metabolic function in women with polycystic ovary syndrome (PCOS).
- Conditions
- Pre Diabetes, Polycystic Ovary Syndrome, Obesity Android
- Trial name
- SAXAPCOS (NCT03480022)
- Testing
- Liraglutide Pen Injector [Saxenda]
- Where
- United States
- Volunteers
- 88 people
- Sponsor
- Woman's
Diabetes Mellitus Type 2
Risk of Nocturnal Hypoglycemia and Arrhythmias With Sitagliptin Versus Glimepiride in Patients With Type 2 Diabetes
This exploratory double blind randomized active controlled study is designed to assess the effects of a treatment with therapeutical dosage of sitagliptin versus therapeutical dosage of glimepiride as add on therapy in patients…
- Trial name
- NCT02373865
- Testing
- Sitagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 4 people
- Sponsor
- GWT-TUD GmbH
Diabetes Mellitus, Type 2
Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)
The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus.
- Trial name
- NCT00767000
- Testing
- MK-0941, Lantus, Metformin
- Volunteers
- 813 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of PF-06882961 in Chinese Adults With Type 2 Diabetes Mellitus
This is a Phase 1, randomized, double-blind (sponsor open), placebo controlled study in adult Chinese participants with T2DM who are receiving metformin as background antihyperglycemic medication.
- Trial name
- NCT04889157
- Testing
- PF-06882961
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Pfizer
Type 2 Diabetes, Sedentary Behavior
Sit Less Program for Patients With Type 2 Diabetes
This randomized controlled trial aims to evaluate an 8-week intervention designed to reduce sedentary behavior (SB) in patients with type 2 diabetes (T2D) using wearable technology.
- Conditions
- Type 2 Diabetes, Sedentary Behavior, Sedentary Time, Physical Activity
- Trial name
- NCT06457802
- Testing
- Sit Less Program
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Vanderbilt University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.